Postoperative mid-to-long-term adverse event prediction model for patients receiving non-cardiac surgery: An extension of the Simple Postoperative AKI RisK (SPARK) model.

IF 3.9 2区 医学 Q1 UROLOGY & NEPHROLOGY
Clinical Kidney Journal Pub Date : 2025-02-17 eCollection Date: 2025-05-01 DOI:10.1093/ckj/sfaf045
Soie Kwon, Sehoon Park, Sunah Yang, Chaiho Shin, Jeonghwan Lee, Jiwon Ryu, Sejoong Kim, Jeong Min Cho, Hyung-Jin Yoon, Dong Ki Kim, Kwon Wook Joo, Yon Su Kim, Minsu Park, Kwangsoo Kim, Hajeong Lee
{"title":"Postoperative mid-to-long-term adverse event prediction model for patients receiving non-cardiac surgery: An extension of the Simple Postoperative AKI RisK (SPARK) model.","authors":"Soie Kwon, Sehoon Park, Sunah Yang, Chaiho Shin, Jeonghwan Lee, Jiwon Ryu, Sejoong Kim, Jeong Min Cho, Hyung-Jin Yoon, Dong Ki Kim, Kwon Wook Joo, Yon Su Kim, Minsu Park, Kwangsoo Kim, Hajeong Lee","doi":"10.1093/ckj/sfaf045","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Postoperative acute kidney injury (PO-AKI) is a critical complication of adverse kidney outcomes, both short and long-term. We aimed to expand our pre-existing PO-AKI prediction model to predict mid-to long-term adverse kidney outcomes.</p><p><strong>Methods: </strong>We included patients who underwent major non-cardiac surgeries from the original SPARK cohort, two external validation cohorts, and a temporal validation cohort. Mid-to-long-term adverse kidney outcomes were defined as end-stage kidney disease progression or death within 1 or 3 years after surgery. We verified and tuned the original Simple Postoperative AKI RisK (SPARK) model to predict mid-to-long-term adverse kidney events.</p><p><strong>Results: </strong>We included 33 636 patients in development, 71 232 patients in external validation, and 33 944 patients in temporal validation cohorts, respectively. One- and 3-year adverse kidney events occurred in 5.5% and 13.2% in the development cohort, respectively. The original SPARK score demonstrated an acceptable discriminative power for 1-year and 3-year adverse outcome risks with C indices mostly >0.7. However, the power was relatively poor when restricted to high-risk patients or those who actually developed PO-AKI. When we re-calculated the regression coefficients from a Cox model, the discriminative performances were better, especially for those with high-risk characteristics (e.g. 1-year outcome, C-index 0.72 in developmental and 0.73‒0.77 in validation datasets). Furthermore, when the model integrated the PO-AKI stage and history of malignancy with the SPARK variables, the performance was significantly enhanced (1-year, C-index 0.86 in development and 0.86‒0.88 in validation results). With the above findings, we constructed an online postoperative risk prediction system (https://snuhnephrology.github.io/postop/).</p><p><strong>Conclusions: </strong>The addition of two clinical factors and recalibration of SPARK variables significantly improved mid-to-long-term postoperative risk prediction for mortality or dialysis after non-cardiac surgery. Our calculator helps clinicians easily predict a mid-to-long-term risk and PO-AKI occurrence by entering a few variables.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 5","pages":"sfaf045"},"PeriodicalIF":3.9000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12044331/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Kidney Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ckj/sfaf045","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Postoperative acute kidney injury (PO-AKI) is a critical complication of adverse kidney outcomes, both short and long-term. We aimed to expand our pre-existing PO-AKI prediction model to predict mid-to long-term adverse kidney outcomes.

Methods: We included patients who underwent major non-cardiac surgeries from the original SPARK cohort, two external validation cohorts, and a temporal validation cohort. Mid-to-long-term adverse kidney outcomes were defined as end-stage kidney disease progression or death within 1 or 3 years after surgery. We verified and tuned the original Simple Postoperative AKI RisK (SPARK) model to predict mid-to-long-term adverse kidney events.

Results: We included 33 636 patients in development, 71 232 patients in external validation, and 33 944 patients in temporal validation cohorts, respectively. One- and 3-year adverse kidney events occurred in 5.5% and 13.2% in the development cohort, respectively. The original SPARK score demonstrated an acceptable discriminative power for 1-year and 3-year adverse outcome risks with C indices mostly >0.7. However, the power was relatively poor when restricted to high-risk patients or those who actually developed PO-AKI. When we re-calculated the regression coefficients from a Cox model, the discriminative performances were better, especially for those with high-risk characteristics (e.g. 1-year outcome, C-index 0.72 in developmental and 0.73‒0.77 in validation datasets). Furthermore, when the model integrated the PO-AKI stage and history of malignancy with the SPARK variables, the performance was significantly enhanced (1-year, C-index 0.86 in development and 0.86‒0.88 in validation results). With the above findings, we constructed an online postoperative risk prediction system (https://snuhnephrology.github.io/postop/).

Conclusions: The addition of two clinical factors and recalibration of SPARK variables significantly improved mid-to-long-term postoperative risk prediction for mortality or dialysis after non-cardiac surgery. Our calculator helps clinicians easily predict a mid-to-long-term risk and PO-AKI occurrence by entering a few variables.

非心脏手术患者术后中长期不良事件预测模型:简单术后AKI风险(SPARK)模型的扩展
背景:术后急性肾损伤(PO-AKI)是短期和长期肾脏不良结局的重要并发症。我们的目标是扩展现有的PO-AKI预测模型,以预测中长期肾脏不良结局。方法:我们纳入了来自原始SPARK队列、两个外部验证队列和一个时间验证队列的接受重大非心脏手术的患者。中长期肾脏不良预后定义为手术后1 - 3年内终末期肾脏疾病进展或死亡。我们验证并调整了原始的简单术后AKI风险(SPARK)模型来预测中长期肾脏不良事件。结果:我们分别纳入了33 636例处于开发阶段的患者、71 232例处于外部验证阶段的患者和33 944例处于时间验证阶段的患者。在发展队列中,1年和3年肾脏不良事件发生率分别为5.5%和13.2%。原始SPARK评分对1年和3年不良结局风险具有可接受的判别能力,C指数大多为bb0 0.7。然而,当仅限于高风险患者或实际发生PO-AKI的患者时,这种能力相对较差。当我们从Cox模型中重新计算回归系数时,判别性能更好,特别是对于那些具有高风险特征的数据(例如,1年结局,发育数据集的c指数为0.72,验证数据集的c指数为0.73-0.77)。此外,当该模型将PO-AKI分期和恶性肿瘤病史与SPARK变量结合时,其性能显著增强(1年,开发c指数为0.86,验证结果为0.86 - 0.88)。基于以上发现,我们构建了一个在线术后风险预测系统(https://snuhnephrology.github.io/postop/)。结论:两个临床因素的加入和SPARK变量的重新校准显著提高了非心脏手术后死亡或透析的中长期术后风险预测。我们的计算器通过输入一些变量帮助临床医生轻松预测中长期风险和PO-AKI的发生。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Kidney Journal
Clinical Kidney Journal Medicine-Transplantation
CiteScore
6.70
自引率
10.90%
发文量
242
审稿时长
8 weeks
期刊介绍: About the Journal Clinical Kidney Journal: Clinical and Translational Nephrology (ckj), an official journal of the ERA-EDTA (European Renal Association-European Dialysis and Transplant Association), is a fully open access, online only journal publishing bimonthly. The journal is an essential educational and training resource integrating clinical, translational and educational research into clinical practice. ckj aims to contribute to a translational research culture among nephrologists and kidney pathologists that helps close the gap between basic researchers and practicing clinicians and promote sorely needed innovation in the Nephrology field. All research articles in this journal have undergone peer review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信